News

What does this smart money investor see that the market is missing?

Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.

AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.

Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.

Earlier this week, the European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with AVD chemotherapy as the first immunotherapy-based frontline regimen for adults and adolescents with previously untreated Stage III or IV classical Hodgkin lymphoma in the EU. This decision expands Opdivo’s reach into earlier-stage treatment of a cancer that is especially common in adolescents and young adults, potentially broadening Bristol Myers Squibb’s hematology-oncology...

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason — five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

Bristol Myers Squibb (NYSE:BMY) received European Commission approval for Opdivo plus AVD as the first immunotherapy-based first-line regimen for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents. At ASCO 2026, the company reported late-breaking Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma, with a 52% reduction in disease progression or death. Izalontamab brengitecan Phase 3 data at the same meeting indicated meaningful survival...

Durability, not yield, is the deciding factor.

If enacted, lawmakers will hold the right to monitor and restrict American companies from signing certain deals with Chinese entities.

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Whichever one you choose, you'll need patience before you can see solid returns.

Bristol-Myers Squibb has underperformed the Dow recently, yet analysts remain moderately optimistic about the stock’s prospects.

Bristol Myers secured EU approval for Opdivo plus AVD in newly diagnosed advanced cHL and advanced Camzyos' label expansion review.

Bristol-Myers Squibb (BMY) continues to draw attention as investors weigh its current share price of US$54.95 against recent share performance and fundamentals, including revenue of US$48.5b and net income of US$7.3b. See our latest analysis for Bristol-Myers Squibb. The recent 7 day share price return fell 7.58% and the 90 day share price return is down 10.24%, yet the 1 year total shareholder return of 18.25% points to momentum that has been positive over a longer window. If you are...

Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.

Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced melanoma.

BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.

Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.

Bristol Myers Squibb (NYSE:BMY) has secured approval from the European Commission for the use of Opdivo (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) as a first-line treatment for adults and adolescents aged 12 years and older with previously untreated Stage III or Stage IV classical Hodgkin lymphoma. The decision introduces the first immunotherapy-based treatment regimen approved in the European Union for patients newly diagnosed with advanced classical Hodgkin

AstraZeneca added to its Imfinzi armamentarium on Monday after the immuno-oncology drug led to improved survival in liver cancer patients.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceuticals stocks fared in Q1, starting with Bristol-Myers Squibb (NYSE:BMY).

Summit said Harmoni-6 is the first Phase 3 study to show a "statistically significant" survival advantage over a PD-1 inhibitor plus chemotherapy.

Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects

Illumina (NasdaqGS:ILMN) has launched new oncology research tools, including the fully automated fireflyGO platform for targeted cancer workflows. The company has expanded its research panels for solid and blood cancers, aiming to support more precise tumor profiling. Illumina introduced its first distributed whole genome MRD research kit, validated with partners such as Mayo Clinic and highlighted with Bristol Myers Squibb at ASCO. For investors tracking Illumina, this update adds product...

Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced treatment.

Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.

A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.

Bristol Myers Squibb said Friday its drug, mezigdomide, lowered the risk of progression or death for multiple myeloma patients by over half.